PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neurourol Urodyn. Author manuscript; available in PMC 2017 April 26.
Published in final edited form as:
PMCID: PMC5269519
NIHMSID: NIHMS807771

Phenotyping women with detrusor underactivity by presumed etiology: is it plausible?

Abstract

Aims

Underactive bladder (UAB) is a symptom complex with poorly characterized causation. The aim of this study was to determine if clinical and UDS parameters differed between categories of presumed detrusor underactivity (DU) etiologies.

Methods

A retrospective review was performed at a single institution from 2011-2015 to identify patients with symptoms of UAB. Patients were excluded if they were male, had anti-incontinence or pelvic organ prolapse (POP) surgery within 1 year, or the UDS did not demonstrate DU as defined within. Subjects were stratified by etiology into 4 cohorts: cardiovascular disease manifestations (CV), cardiac risk factors (CVR), neurologic (N), or idiopathic (I). Patient demographics, comorbidities, symptomatology, physical exam, and UDS parameters were compared.

Results

200 patients met inclusion criteria [CV: n=53 (26.5%), CVR: n=44 (22%) N: n=81 (40.5%), I: n=22 (11%)]. Women in the CV cohort were significantly older and more likely to be post-menopausal (p<0.001). There were no differences between cohorts for BMI (p=0.48), recurrent UTI (p=0.63), history of urinary retention (AUR) (p=0.65), POP (0.49), American Urological Association Symptom Score (p=0.06), presenting symptomatology [urgency, frequency, urgency urinary incontinence, AUR, incomplete emptying, hesitancy, UTI (p=0.97)], or UDS parameters [first sensation (p=0.25), normal desire (p=0.80), strong desire (p=0.58), capacity (p=0.11), Qmax (p=0.50), Pdet at Qmax (p=0.22), post-void residual (p=0.82)].

Conclusions

Though differences were observed between cohorts for age and menopausal status, clinical or urodynamic parameters did not demonstrate distinct differences across presumed categories of etiology, suggesting that the etiology of DU may be multifactorial.

Introduction

Underactive bladder (UAB) is a poorly understood clinical symptom complex lacking a definition consensus, but is known to involve incomplete or inefficient bladder emptying in the absence of significant bladder outlet obstruction (BOO). Frequently associated symptoms include hesitancy, straining to void, incomplete emptying, urgency, frequency, nocturia, urinary incontinence (UI), and recurrent urinary tract infections (UTIs).1 Chapple et al. proposed a working definition for UAB: “a symptom complex suggestive of detrusor underactivity (DU), usually characterized by prolonged urination time with or without a sensation of incomplete bladder emptying, usually with hesitancy, reduced sensation on filling, and a slow stream.”2 However, UAB symptomatology may be clinically indistinguishable from BOO.3 As such, UAB is currently indexed by identifying DU on urodynamics (UDS). The International Continence Society (ICS) defines DU as, “a detrusor contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or failure to achieve complete bladder emptying within a normal time span.”4

The etiology of DU, and thus the development of UAB symptoms remain unclear. DU has been associated with neurologic, idiopathic, iatrogenic, and myogenic factors, which can result from common comorbid conditions.3 It has been identified in 12-45% of older women undergoing UDS for lower urinary tract symptoms.3,5 DU is also independently associated with increased age and is often cited as an indication for bladder catheterization in elderly, institutionalized patients.6

The aim of this study was to determine if clinical and urodynamic parameters differed between categories of presumed DU etiologies. The rationale is that if clinical phenotypes can be identified for patients who present with symptoms of UAB, it may improve our understanding of this complicated disease process as well as guide future management and treatment options.

Materials and Methods

After Institutional Review Board approval, a retrospective chart review was performed to identify all patients with UAB at our institution from 2011-2015 using the International Classification of Diseases, version 9 diagnosis codes representative of UAB symptomatology (ICD-9): urinary retention (788.2x, 788.20, 788.29), incomplete emptying (788.21), slowing of urine stream (788.62), hesitancy (788.64), straining (788.65), atony of bladder (596.4), paralysis of bladder (596.53), and neurogenic bladder (596.54). Each UDS was reviewed to identify patients with DU using the current ICS definition.4 Patients were excluded from the study if they were male, if there was a history of anti-incontinence or pelvic organ prolapse (POP) surgery within 1 year, or if the UDS showed BOO or did not demonstrate DU. Patients without a UDS available for independent review were also excluded.

Patient demographics, comorbidities, symptomatology, physical exam findings, American Urological Association Symptom Score (AUA-SS) questionnaire results, and UDS parameters were assimilated. Patients were stratified into 4 cohorts based on the potential underlying etiology, determined by the medical history. Inclusion criteria for the neurologic (N) cohort comprised diagnoses of: spinal cord injury, Parkinson's disease, multiple sclerosis, cerebrovascular accident (CVA) with neurologic sequelae, spinal surgery, peripheral neuropathy of any etiology including diabetes mellitus (DM), and other neurologic conditions. Inclusion criteria for the cardiovascular disease manifestations (CV) cohort required that the disease was severe enough to necessitate surgical or endoscopic intervention for: severe coronary artery disease (CAD), severe peripheral vascular disease (PVD) or myocardial infarction (MI), cardiac arrhythmia, CVA, and structural/valve disease. Patients with a diagnosis of CAD or PVD managed with medical therapy alone were considered to be at risk for severe cardiac disease and included into a cardiac risk factor cohort (CVR). This cohort also included patients with hypertension, hyperlipidemia, DM without peripheral neuropathy, and tobacco use. All other patients were assigned to the idiopathic (I) cohort. The investigators assigned patients with multiple etiologies to the cohort for which the patient exhibited the most severe disease manifestations.

Patient variables were then compared between cohorts using t–test or Fisher exact test statistics. Statistical analyses were performed to identify individual predictors associated with DU. The criterion for statistical significance was set at p <0.05. The statistical software program STATA version 13 (College Station, TX) was employed for all statistical analysis.

Results

Of the 200 women included in the study, 53 (26.5%) were categorized as CV; 44 (22%) as CVR; 81 (40.5%) as N; and 22 (11%) as I. Patient demographics, comorbidities, physical exam findings, and UDS are shown in Table I. Mean age was 61.9 ±15.8 years (range 23 to 91).

Table I
Patient Demographics.

There were no differences between cohorts for BMI (p=0.48), recurrent UTI (p=0.63), history of urinary retention (AUR) (p=0.65), or POP (0.49). AUA-SS was available for 98 of 200 patients, and also did not differ across categories (p=0.06) (Table II). There was no difference between groups in presenting symptomatology: urgency, frequency, urgency urinary incontinence (UUI), AUR, incomplete emptying, hesitancy, or UTI, (p=0.97). Women in the CV cohort were significantly older (p<0.001) and more likely to be post-menopausal (p<0.001).

Table II
Statistical analysis of patient variables by cohort.

Urodynamic parameters [first sensation (p=0.25), normal desire (p=0.80), strong desire (p=0.58), capacity (p=0.11), Qmax (p=0.50), Pdet at Qmax (p=0.22), and post-void residual (PVR), (p=0.82)] did not significantly differ between cohorts (Table III). Detrusor overactivity (DO) was observed in 28 patients (14%) and compliance abnormalities were present in 15 patients (7.5%) and did not differ between groups (p=1.00, p=0.67, respectively).

Table III
Urodynamic parameters by cohort.

Treatments for UAB symptomatology included self-intermittent catheterization (SIC) in 160 patients (80%), sacral neuromodulation and SIC in 17 patients (8.5%), sacral neuromodulation alone in 9 patients (4.5%), indwelling Foley catheter in 2 patients (1%), and other treatment in 12 patients (6%). Of the 26 patients treated with sacral neuromodulation: 6 (23%) were included in CVR; 6 (23%) in N; 4 (15%) in CV; and, 10 (39%) in I. Of these 10 patients without a neurologic or cardiac etiology, 6 presented with complex voiding dysfunction with incomplete emptying on UDS. Overall, 65% (17/26) of the patients treated with sacral neuromodulation had at least one episode of AUR in the clinical history, with 42% (11/26) having AUR as the initial presenting symptom.

Discussion

Our study identified differences in age and menopausal status between cohorts; patients with DU and extensive cardiovascular disease appear to be older. Age has been found to be independently associated with DU in prior studies.6 However, we were unable to identify any other clinical or urodynamic associations between groups. This inability to identify clinical phenotypes in women with DU is also consistent with the existing literature, suggesting that the underlying etiology for DU may be multifactorial.

It has been proposed that DU can result from neurologic, myogenic, iatrogenic, or idiopathic causes.3 The myogenic hypothesis suggests that smooth muscle changes within the bladder leading to reduced excitability and loss of intrinsic muscle contractility, which drives spontaneous detrusor contractions.7 Osman et al. include BOO and DM as myogenic causes for DU.3 The neurogenic hypothesis suggests defects in afferent innervation or the integrative control at spinal and supraspinal centers lead to poor efferent outflow.8 Iatrogenic causes may be related to denervation from pelvic surgery, radical hysterectomy, or anterior/abdominoperineal resection, and thus may be considered neurogenic as well.

Epidemiological studies have suggested bladder ischemia, hypoxia, and metabolic syndrome are likely etiological factors of DU, though the pathological mechanisms have not been clearly defined.7 In animal models, cystometry of MI-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits showed significantly shorter micturition intervals, smaller voided volume with non-voiding contractions, and lower micturition pressure compared to controls.7 Vascular compromise can be represented by CV risk factors: tobacco use, hyperlipidemia, hypertension, and DM. As such, it appears that DU in women may primarily be due to neurologic, early or late CV disease, or may be idiopathic in nature. As such, we elected to evaluate patients using these 4 cohorts.

While there are several review articles discussing the inherent difficulties in defining and treating symptoms of UAB, there is a paucity of literature evaluating patients with DU using actual clinical data. Gammie et al. evaluated a large UDS database of 1,788 patients to identify clinical features associated with DU. The study identified interrupted urinary stream, absent and/or decreased sensation, incomplete bladder emptying, and hesitancy for women with DU (n=308).9 While this symptomatology supports the proposed definition by Chapple et al.2, the study does not identify any differences in etiology or clinical history among patients with DU. Several small series have attempted to identify predictive factors for impaired detrusor contractility in men, but similar to our study in women, failed to identify any significant differences.10,11 Hoag et al. evaluated 79 patients with DU, 68.4% of which were female. The most common symptoms were: urgency (63.3%), weak stream (61.0%), straining (57.0%), nocturia (48.1%), and frequency (46.8%). Among patients who were able to void, mean Pdet @ Qmax was 22.3 (5-37) and mean Qmax was 9.3 (1-22), which is similar to the value in our study. Surgical history (pelvic 40.5%, back 19.0%), DM (11.4%), and medications promoting AUR (32.9%) were cited as the most prevalent risk factors, but the study did not address any other patient characteristics.12 To our knowledge, our study is the largest series to date to evaluate potential underlying etiologies of female patients with DU and assess urodynamic parameters and clinical factors contributing to their UAB symptomatology.

Several study limitations are noteworthy. As a retrospective review, ICD-9 diagnosis codes were used to identify patients with symptoms of UAB. Unfortunately, there is not an ICD-9 code for UAB specifically, which may have prevented the electronic search from including all potential patients. As a result, codes were used which represent established symptoms of UAB, and then UDS were independently reviewed to identify patients with DU. Since there is not currently a universal measurement to define DU, our use of Pdet @ Qmax as an index of bladder contractility may have also limited our findings. Men were excluded from the study due to the potentially different pathophysiologies in men and women, as in the case of BOO secondary to benign prostatic enlargement in men.13,14

DO was present in 14% of the patients. The presence of both DO and DU may have confounded the UDS analysis, limiting our ability to identify associations between groups. Chancellor recently hypothesized that chronic untreated or treatment-refractory overactive bladder (OAB) may progress to detrusor hyperreflexia/impaired contractility (DHIC) and ultimately UAB.15 As such, these 14% may represent patients with DHIC on this continuum rather than a unique disease state. However, further study is needed to substantiate this hypothesis.

Patients were stratified into cohorts using predefined criteria; yet, many patients had comorbidities across all 4 cohorts, and stratifying them by the most significant manifestations may have introduced bias. Previous studies have categorized DM as either a neurogenic16 or myogenic etiology.1 We were unable to accurately measure the severity of the disease or the clinical time course for all patients; thus, we assigned patients with DM without peripheral neuropathy to the CVR cohort, and those with peripheral neuropathy to the N cohort. Diabetic cystopathy, which can include symptoms of sensory-urgency, impaired bladder emptying, and DU, can occur in up to 50% of patients with DM and may be due to peripheral neuronal dysfunction and/or microvascular disease.7 As such, certain comorbidities could not be compartmentalized due to the presence of neurologic and cardiovascular compromise, suggesting that the etiology of DU may truly be multifactorial.

Conclusions

Though differences were observed between cohorts for age and menopausal status, categorizing patients by clinical or urodynamic parameters did not demonstrate distinct differences, suggesting that the etiology of DU may be multifactorial. As in the existing literature, we were unable to identify common characteristics, which also suggests that the pathophysiology of DU still remains unclear. As a result, future opportunities exist to identify clinical phenotypes for patients presenting with UAB symptomatology.

Acknowledgments

Funding

This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number K23DK103910 and the National Center for Advancing Translational Sciences under CTSA award number UL1TR000445. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of Vanderbilt University, the National Center for Advancing Translational Sciences, or the National Institutes of Health.

References

1. Miyazato M, Yoshimura N, Chancellor MB. The other bladder syndrome: underactive bladder. Rev Urol. 2013;15:11–22. [PubMed]
2. Chapple CR, Osman NI, Birder L, et al. The underactive bladder: a new clinical concept? Eur Urol. 2015;68:351–53. [PubMed]
3. Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, Koelbl H, van Kerrebroeck P, Wein AJ. Detrusor Underactivity and the Underactive Bladder: A New Clinical Entity? A Review of Current Terminology, Definitions, Epidemiology, Aetiology, and Diagnosis. Eur. Urol. 2014;65:389–398. [PubMed]
4. Haylen BT, deRidder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20. [PubMed]
5. Cohn J, Brown ET, Kaufman M, et al. Underactive bladder in women: is there any evidence? Curr Opin Obstet Gynecol. 2016;26(00):1–6.
6. Pfisterer MH, Griffiths DJ, Schaefer W, et al. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc. 2006;54(3):405–12. [PubMed]
7. Tyagi P, Smith P, Kuchel G, et al. Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol. 2014;46(Suppl 1):S11–21. [PMC free article] [PubMed]
8. Liao L, Schaefer W. Within-session reproducibility and variability of urethral resistance and detrusor contractility in pressure flow studies in men with lower urinary tract symptoms. Curr Urol. 2009;3(1):19–28.
9. Gammie A, Kaper M, Dorrepaal C. Signs and symptoms of detrusor underactivity: an analysis of clinical presentation and urodynamic tests from a large group of patients undergoing pressure flow studies. Eur Urol. 2015;6377:1–9. [PubMed]
10. Wang CC, Yang SS, Chen YT, et al. Video urodynamics identifies the causes of young men with lower urinary tract symptoms and low uroflow. Eur Urol. 2003;43:386–90. [PubMed]
11. Jeong SJ, Jeong JS, Lee JK, et al. Chronic lower urinary tract symptoms in young men without symptoms of chronic prostatitis: urodynamic analyses in 308 men with aged 50 years or younger. Korean J Urol. 2014;55:341–8. [PMC free article] [PubMed]
12. Hoag N, Gani J. Underactive bladder: clinical features, urodynamic parameters, and treatment. Int Neurourol J. 2015;19:185–89. [PMC free article] [PubMed]
13. Smith P, Birder L, Abrams P, et al. Detrusor underactivity and the underactive bladder: symptoms, function, cause-what DO we mean? ICI-RS Think Thank. Neururol Urodyn 2016. 2014;35:312–317. [PubMed]
14. van Koeveringe GA, Rademakers K, Birder L, et al. Detrusor underactivity: pathophysiological considerations, models and proposals for future research. ICI-RS. Neurourol Urodyn 2014. 2013;33:591–96. [PMC free article] [PubMed]
15. Chancellor M. B.: The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014;46:S23–S27. [PubMed]
16. Kadow B, Tyagi P, Chermansky C. Neurogenic causes of detrusor underactivity. Curr Bladder Dysfunct Rep. 2015;10:325–331. [PMC free article] [PubMed]